1. Panduan & Polisi Mengenai Proses Penyaringan Darah Oleh: En. Abd
Panduan & Polisi Mengenai Proses Penyaringan Darah Oleh: En. Abd. Hamid Bon B.Sc(Hons), M.Sc.,D.M.M.,D.A.P&E Pegawai Sains Kanan Pusat Darah Negara

2. Policy On Screening Activities ( Ref: (21)dlm. KKM-171(9971)Bhg. 2 bth
Policy On Screening Activities ( Ref: (21)dlm.KKM-171(9971)Bhg.2 bth. 2 March 1998 )
Safety of blood transfusion services through;
Mandatory screening of blood donors through donated blood
Blood products to be used judiciously
Imported blood to be certified free of HIV

3. OTHERS
Informed consent to be obtained; pre and post test counseling to be given to individuals undergoing HIV testing
Voluntary confidential screening of individuals

4. Blood Safety Approaches
Donor Selection
Serological Screening
NAT Testing
Viral Inactivation
Vaccination

5. Remaining Risks Window Period (Pre-Seroconversion ) Viral Variants
Atypical Seroconversion/ Immunosilent
Laboratory Error

7. (ESTABLISHED/MULTIPLY) NO VIRUS FOUND IN THE BLOOD
PATHOGENESIS PHASE
INFECTION
ECLIPSE
(ESTABLISHED/MULTIPLY)
NO VIRUS FOUND IN THE BLOOD
INFECTIOUS PHASE (WINDOW PERIOD )
(AFTER ECLIPSE & BEFORE SEROCONVERSION)
SEROCONVERTION
(ANTIBODY PRODUCTION)

8. Screening for Infectious Markers ( (Transfusion Practice Guidelines: update version )
Specific approach to ensure quality
of the screening procedure rely on;
Training of staff
Assessment of staff capability
Maintenance and calibration of equipments
Monitoring of storage conditions
of test materials and reagents

9. >Include external control and to monitor through statistical process control
>Use validate/approved test kit by authorized body/organisation
>Repeat testing of Initial Reactive in duplicate together with blood bag sample by the same assay
>Take part in external proficiency exercises

10. Removal of all reactive blood/products from the quarantine refrigerator
Disposal off all reactive blood/products
All the results must be verified by authorized personnel

11. Documentation
Of All
The Above
Actions !

12. Screening Disease Screening Supplemental Test Confirmation Test
HIV 1&2
( Anti-HIV)
EIA PA
ImmunoBlot
(LIA )
HBV
( HBsAg )
Anti-HBc
Anti-HBe
Anti-HBs
HBe
Neutralisation
HCV
(Anti-HCV )
NONE
RIBA-3
(HCV-RNA)
Syphilis
VDRL
RPR
VDRL (Dilution)
TP-PA

13. Others Malaria Penderma-penderma dari kumpulan berisiko tinggi
(Ref: Bil(41)dlm.RKPBV/S/80/98 bth. 2 Feb )
Penderma-penderma dari kumpulan berisiko tinggi
Anggota tentera
Anggota polis hutan
Penduduk dirancangan Pembukaan Tanah (Felda, Felcra dll) dikawasan bermalaria

14. Pekerja di”logging camps” dikawasan bermalaria
Pelawat ke negeri-negeri berjiran yang bermasalah malaria

15. Simple Rapid Test ( Ref: bil(55)dlm. KKM-87(467)Bhg. 18 bth. 27 Feb
Simple Rapid Test is NOT Recommended for Donor Screening ( HIV )
Simple Rapid Test for HIV Testing MUST always be Backed up by the EIA Test.

16. Blood Screening/Release Flow-Chart Ref: bil(2)dlm. K31350 Bhg. 12 bth
Blood Screening/Release Flow-Chart Ref: bil(2)dlm. K31350 Bhg. 12 bth.3 Okt.1991 Ref: Transfusion Practice Guidelines for Clinician & Lab. Personel
Algorithm for HIV_HBV_HCV.xls

17. Management of Reactive Sample (Ref: bil (2)dlm. K31358 Bhg. 12 bth
Management of Reactive Sample (Ref: bil (2)dlm. K31358 Bhg.12 bth.3Okt.1991 and Transfusion Practice Guidelines-Update Version )
Initial Reactive Donation Sample must be Retested in Duplicate by the same assay
If Any of the Repeat Test are Reactive, then the donations are considered as Repeatedly Reactive
To check and tally results of PT/SG
The status of Repeatedly Reactive Donation Sample should be confirmed ( Sent to PDN for HIV and HCV )

18. Sample Referred for Confirmation ( Ref: bil. (41) dlm. KKM
Sample Referred for Confirmation ( Ref: bil.(41) dlm. KKM.87( P20505 ) Bhg.4 bth. Feb.2001)
Donation samples of Repeatedly Reactive for HIV and HCV
( Sample from Blood Bag )
Fill-up the form
HIV ( Borang 1 : TML-PDN-1 )
HCV ( Borang 2 : TML-PDN-2 )

19. Sample Referred for HCV-RNA PCR
Sample Repeatedly Reactive with Anti-HCV EIA
RIBA-3 Indeterminate Twice
Time period between first and second RIBA-3 Indeterminate results must be in 6 months
Fill-up form Borang 3 ( TML-PDN-2A )

20. Sample Referred for HCV 2002
Appendix for PD Presentation.doc

21. Sample Referred for HIV 2002
Appendix for PD Presentation.doc

22. Algorithm WHO Algorithm for HIV ( Ref: bil(55) dlm. KKM-87(467) Bhg.18
bth.27 feb )
Lampiran 5 ( Strategy III )
Algorithm for HIV_HBV_HCV.xls

23. Study/Research
Appendix for PD Presentation.doc

24. THANK YOU